Gastroenteropancreatic Neuroendocrine Tumors Gep Nets Epidemiology Forecast

DelveInsight's 'Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.


Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Understanding

The DelveInsight Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) epidemiology report gives a thorough understanding of the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in the US, Europe, and Japan. The report covers the detailed information of the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) epidemiology scenario in seven major countries (US, EU5, and Japan).


Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology Perspective by DelveInsight

The Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.


Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Detailed Epidemiology Segmentation

The Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) epidemiology covered in the report provides historical as well as forecasted Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.


Scope of the Report

  • The Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology Report and Model provide an overview of the risk factors and global trends of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
  • The report provides the segmentation of the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) epidemiology


Report Highlights

  • 11-Year Forecast of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) epidemiology
  • 7MM Coverage
  • Total Cases of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
  • Total Cases of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) according to segmentation
  • Diagnosed cases of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)


KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.


Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)?
  • What are the key findings pertaining to the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)?
  • What are the currently available treatments of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)?


Reasons to buy

  • The Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) market
  • Quantify patient populations in the global Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) therapeutics in each of the markets covered
  • Understand the magnitude of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) population by its epidemiology
  • The Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights 

2. Executive Summary of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

3. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Treatment and Management

6.2. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Table 1  Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in 7MM (2017-2030)

Table 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in 7MM (2017-2030)

Table 3 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in the United States (2017-2030)

Table 4 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in the United States (2017-2030)

Table 5 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in Germany (2017-2030)

Table 6 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in Germany (2017-2030)

Table 7 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in France (2017-2030)

Table 8 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in France (2017-2030)

Table 9 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in Italy (2017-2030)

Table 10 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in Italy (2017-2030)

Table 11 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in Spain (2017-2030)

Table 12 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in Spain (2017-2030)

Table 13 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in the United Kingdom (2017-2030)

Table 14 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Table 15 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in Japan (2017-2030)

Table 16 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in Japan (2017-2030)

Figure 1 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in 7MM (2017-2030)

Figure 2 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in 7MM (2017-2030)

Figure 3 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in the United States (2017-2030)

Figure 4 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in the United States (2017-2030)

Figure 5 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in Germany (2017-2030)

Figure 6 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in Germany (2017-2030)

Figure 7 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in France (2017-2030)

Figure 8 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in France (2017-2030)

Figure 9 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in Italy (2017-2030)

Figure 10 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in Italy (2017-2030)

Figure 11 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in Spain (2017-2030)

Figure 12 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in Spain (2017-2030)

Figure 13 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in the United Kingdom (2017-2030)

Figure 14 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in the United Kingdom (2017-2030)

Figure 15 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Epidemiology in Japan (2017-2030)

Figure 16 Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Diagnosed and Treatable Cases in Japan (2017-2030)

*The table of contents is not exhaustive; will be provided in the final report



  • Tags:
  • Gastroenteropancreatic Neuroendocri...
  • Gastroenteropancreatic Neuroendocr...
  • Gastroenteropancreatic Neuroendocr...
  • Gastroenteropancreatic Neuroendocr...
  • Gastroenteropancreatic Neuroendocr...
  • Gastroenteropancreatic Neuroendocr...
  • Gastroenteropancreatic Neuroendocr...
  • Gastroenteropancreatic Neuroendocr...

Forward to Friend

Need A Quote